Peptide News Digest

#Foundayo

76 stories

Foundayo is Eli Lilly's brand name for orforglipron, the first small-molecule GLP-1 pill approved for obesity. The FDA cleared it in early April 2026; the IQVIA launch tracker has stepped up from 3,707 prescriptions in Week 2 to 5,612 in Week 3 to 7,335 in Week 4 (the week ending May 1, per Citi's May 8 client note). Citi flagged that the IQVIA data captures retail and partial telehealth, likely understating Lilly Direct and the 12+ telehealth firms that account for roughly 35% of launch volume, and Lilly executives have cited 20,000 patients now on the drug. Citi modeled $146M in Q2 and $1.6B for full-year 2026. On the April 30 Q1 call, Lilly disclosed more than 8,000 prescribers (one-third writing an oral GLP-1 for the first time) and 80% of patients new to the GLP-1 class, with commercial access confirmed at two of the three largest US PBMs effective mid-May.

The ACHIEVE-3 obesity Phase 3 gave Foundayo HbA1c superiority versus oral semaglutide in type-2 diabetes, but indirect comparisons published just after launch suggested oral Wegovy may produce greater weight loss with fewer GI discontinuations. Managed Healthcare Executive's head-to-head writeup framed the choice as HbA1c lead versus weight-loss lead. On May 4, an FAERS hepatic-failure case in a 56-year-old male, logged April 30, surfaced publicly. LLY fell 3% premarket before recovering as Lilly released updated safety data the FDA had requested, citing no DILI signal across the 11,000-patient ACHIEVE+ATTAIN program. RBC Capital framed the case as 'baseline noise' and pointed to comparable hepatic-failure tallies for Mounjaro (30), Ozempic (33), Wegovy (15), and Zepbound (2).

The first full commercial quarter view landed on the Eli Lilly Q2 2026 earnings call Wednesday August 5, 2026 with Foundayo generating $98 million in revenue during its first fully operational quarter, providing the first commercial-earnings-line view of the oral small-molecule GLP-1 category. Lilly's combined obesity/diabetes franchise (Mounjaro + Zepbound + Foundayo) reached $14.9 billion in the quarter with LLY shares rising approximately 4% intraday on the earnings and guidance beat. On October 1, 2026, the Phase 3 ACHIEVE-4 trial in 2,749 adults with type 2 diabetes and increased cardiovascular risk, published in The Lancet, showed Foundayo was noninferior to insulin glargine on major heart events (MACE-4 hazard ratio 0.84; 95% CI 0.59 to 1.20). On October 15, 2026, the EMA's CHMP recommended EU approval for weight management and type 2 diabetes, pending a European Commission decision. Australia's TGA cleared Foundayo in November 2026, weeks after the Wegovy pill; it launched on private prescription without a Pharmaceutical Benefits Scheme listing.

Stories here cover prescription volumes, payer coverage, head-to-head comparisons with oral Wegovy, and side-effect signals from FAERS. See #orforglipron for the underlying molecule and #oral-glp-1 for class context.

Regulatory · View digest

7NEWS: Australia's TGA Clears Foundayo, the Second GLP-1 Weight-Loss Pill After the Wegovy Pill

Australia's Therapeutic Goods Administration has cleared Lilly's daily Foundayo pill for weight management and type 2 diabetes, 7NEWS reported on November 17 Australian time, weeks after the Wegovy pill was approved. It is available by private prescription but not yet listed on the Pharmaceutical Benefits Scheme, and Lilly Australia said trials enrolled more than 10,000 patients in 15 countries. Associate Professor Samantha Hocking said obesity and overweight now affect around 13 million Australian adults.

Regulatory · View digest

China Approves Lilly's Orforglipron, the First GLP-1 Weight-Loss Pill Cleared There

China's medicines regulator approved Eli Lilly's orforglipron on November 12, making it the first GLP-1 pill approved in China for weight loss, Reuters reported; until now, Chinese regulators had approved GLP-1 drugs for weight management only as injections. Lilly, which sells the drug as Foundayo in the U.S., did not comment on price. Novo Nordisk's application for its oral Wegovy was accepted in August. A J.P. Morgan analyst has forecast that annual sales of GLP-1 weight-management drugs in China could reach 30 billion yuan ($4.5 billion) within five to seven years, up from an estimated 3 billion to 4 billion yuan now.

Clinical Trials · View digest

Lilly's Foundayo Pill Cut Sleep Apnea Severity by Up to 44% Over 52 Weeks in Phase 3 Results Published in JAMA

In adults with overweight or obesity who did not use a positive airway pressure machine, sleep apnea severity fell 43.8% on Lilly's once-daily orforglipron over 52 weeks, and it fell 27.5% in those who did use one; both groups lost about 28 pounds on average, Scientific American reported on November 9. Lilly plans to file with the FDA for moderate to severe obstructive sleep apnea by the end of the year. Daniel Drucker, who was not involved and has consulted for Lilly, said each change to GLP-1 drug structure raises questions about overall and cardiovascular safety.

Research · View digest

Orforglipron Lowered Systolic Blood Pressure 6.1 mmHg vs. 0.8 on Placebo Over 72 Weeks in ATTAIN-1, Post Hoc Analysis Finds

In post hoc analyses of Lilly's Phase 3 ATTAIN-1 (3,127 adults with obesity) and ATTAIN-2 (1,613 adults with obesity and type 2 diabetes) trials, presented at the American Heart Association's Scientific Sessions in Chicago, pooled orforglipron doses lowered office systolic pressure by 6.1 vs. 0.8 mmHg and 4.9 vs. 1.5 mmHg on placebo at 72 weeks. People starting with stage 2 hypertension had the largest drops (15.9 vs. 11.1 and 15.8 vs. 8.2 mmHg), and diastolic pressure fell more than on placebo in ATTAIN-1 but not in ATTAIN-2. Pharmacy Times reported that weight loss explained about 58% and 81% of the systolic change in the two trials.

Industry · View digest

Lilly and Hims & Hers Agree to Offer Zepbound and Foundayo at Lilly's Self-Pay Prices on the Telehealth Platform

Patients prescribed Zepbound (tirzepatide) or Foundayo (orforglipron) by a provider on Hims & Hers can now get Lilly's self-pay prices without leaving the platform, starting at $149 a month for Foundayo and $299 a month for Zepbound, the companies announced November 6. The release says Hims & Hers has never offered compounded copies of Lilly's GLP-1 drugs and has committed not to, and that both companies will protect providers' independent prescribing decisions.

Industry · View digest

Lilly's Third-Quarter Revenue Rose 39% to $24.4 Billion as Mounjaro Hit $10.7 Billion and Zepbound $5.4 Billion

Eli Lilly raised its 2026 revenue forecast to $91 billion to $92 billion, up from $85 billion to $87 billion. Mounjaro sales grew 65%, with $5.7 billion from outside the U.S., Zepbound grew 49%, and the oral GLP-1 Foundayo brought in $184 million. Lilly trimmed its full-year non-GAAP earnings guidance to $35.00 to $36.00 per share after $4.57 per share of acquired research charges in the quarter.

Regulatory · View digest

EMA's CHMP Recommends EU Approval of Lilly's Foundayo, a Once-Daily GLP-1 Pill, for Weight Management and Type 2 Diabetes

The European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion on October 15, 2026, announced October 16, recommending marketing authorization for Eli Lilly's Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist, in film-coated tablets from 0.8 mg to 17.2 mg. The recommended indications cover weight management in adults with a BMI of 30 or more, or 27 to under 30 with at least one weight-related condition, and adults with insufficiently controlled type 2 diabetes, alone when metformin is unsuitable or with other diabetes drugs. The most common side effects are nausea, vomiting, and diarrhea; the European Commission normally decides within 67 days of the opinion.

Clinical Trials · View digest

Lilly's Foundayo Meets Cardiovascular Noninferiority Goal Against Insulin Glargine in Phase 3 ACHIEVE-4, Published in The Lancet

Lilly presented the Phase 3 ACHIEVE-4 trial of its oral small-molecule GLP-1 drug Foundayo (orforglipron) at EASD on Thursday, October 1, 2026, alongside publication in The Lancet. In 2,749 adults with type 2 diabetes, overweight or obesity, and increased cardiovascular risk, Foundayo met its noninferiority goal against insulin glargine for cardiovascular death, heart attack, stroke, or hospitalization for unstable angina (MACE-4 hazard ratio 0.84; 95% CI 0.59 to 1.20); the three-part MACE-3 hazard ratio was 0.77 (95% CI 0.52 to 1.13). At 52 weeks, A1C fell 1.6 points versus 1.0 and weight fell 8.8% versus a 1.7% gain on glargine. Lilly also reported a lower rate of death from any cause (hazard ratio 0.43) but described that analysis as exploratory and not controlled for multiple comparisons; 10.6% of Foundayo patients stopped treatment because of adverse events.

Research · View digest

Lilly Indirect Comparison at EASD Estimates Foundayo 17.2 mg Gives 1.5 Points More Weight Loss Than Oral Semaglutide 25 mg

Lilly announced on Tuesday, September 29, 2026 an indirect treatment comparison, presented at EASD, of its oral small-molecule GLP-1 drug Foundayo (orforglipron) 17.2 mg against Novo's oral semaglutide 25 mg in adults with type 2 diabetes, using data from Lilly's ACHIEVE-3 trial and Novo's PIONEER PLUS trial. At 52 weeks, Foundayo was associated with 1.5 percentage points more weight loss (95% CI -2.7 to -0.2) and a 0.3-point larger A1C reduction (95% CI -0.6 to -0.1); sensitivity analyses gave 1.5 to 2.4 points and 0.3 to 0.6 points. Lilly's Rachel Batterham said head-to-head trials give the best comparison of two medicines, and the two drugs have not been tested directly against each other at these doses.

Industry · View digest

Oral GLP-1 Weekly Prescription Tracker Hits New High: Novo Wegovy Pill Reaches Approximately 183,000 Weekly Total Scripts Per IQVIA Data

The oral GLP-1 launch race entered its ninth month with Novo Nordisk's Wegovy pill (oral semaglutide 25 mg for chronic weight management, U.S. launch January 5, 2026) reaching approximately 183,000 weekly total scripts per the most recent IQVIA week ending September 5, 2026 — the highest weekly total since launch. Eli Lilly's Foundayo (orforglipron, once-daily oral small-molecule non-peptide GLP-1 receptor agonist, U.S. launch April 2026) continued its own prescription climb through the same reporting window. Both products are indicated for adults with obesity or overweight with weight-related comorbidities. Wegovy pill's climb reflects continued Medicare Part D coverage expansion following the November 2025 pricing agreement (Ozempic Pill / Wegovy pill at $149/month per the deal) and CMS 2026 formulary guidance. Foundayo pricing on TrumpRx and cash-pay LillyDirect anchors at $149/month at starting doses. The concurrent oral launch trajectories are the largest test to date of oral incretin adoption relative to the established weekly-injectable class dominated by injectable Wegovy and Zepbound.

Industry · View digest

Eli Lilly Tirzepatide H1 2026 Sales Reach $27.7 Billion (+88% YoY) as Lead Over Novo Nordisk Semaglutide Portfolio Widens to $10.2 Billion

H1 2026 GLP-1 franchise reporting places Eli Lilly (NYSE: LLY) tirzepatide (Mounjaro plus Zepbound) at nearly $27.7 billion in first-half revenue, an 88% year-over-year increase, versus Novo Nordisk (NYSE: NVO) semaglutide (Ozempic plus Wegovy plus Rybelsus plus Wegovy pill) at approximately $17.5 billion. The revenue gap between the two GLP-1 leaders has widened from under $2 billion at the same point last year to $10.2 billion, driven by Zepbound share gains in U.S. obesity following SURMOUNT-5 superiority data over Wegovy, Mounjaro upside in international markets (China +93% CER, Rest of World +136%), Foundayo (orforglipron) first commercial quarter contribution of $98 million, and semaglutide patent expiries approaching in select markets (generic Ozempic expected in Canada). Novo has cut 12,000 positions in H1 2026 and lowered gross margin outlook to 78%, while Lilly raised full-year 2026 revenue guidance to $85-87 billion.

Industry · View digest

Novo Nordisk (NYSE: NVO) Shares Fell Approximately 6% Thursday August 13, 2026 on Broker Downgrade Citing Continued Franchise-Gap Pressure From Eli Lilly's (NYSE: LLY) Tirzepatide Franchise and the CagriSema Head-to-Head Miss Against Tirzepatide (23.0% Versus 25.5% Weight Loss at 84 Weeks in the REDEFINE 4 Head-to-Head Phase 3 Trial); The August 4 H1 2026 Earnings Release Raised Full-Year 2026 Sales Guidance to Down 3% From Prior Down 8% Midpoint but the Broader Investor Narrative Continues to Focus on Novo's Ability to Defend GLP-1 Franchise Economics Against Eli Lilly's Q2 2026 $23 Billion Revenue Blowout (+48% YoY), Foundayo (Orforglipron) $98 Million First Commercial Quarter, and Retatrutide's 28.7% Phase 3 TRIUMPH-4 Weight Loss Result

Novo Nordisk (NYSE: NVO) shares fell approximately 6% Thursday August 13, 2026 on broker downgrade citing continued franchise-gap pressure from Eli Lilly's tirzepatide franchise (Mounjaro + Zepbound) and the CagriSema head-to-head miss against tirzepatide. Specifics: CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg fixed-dose combination) reached 23.0% weight loss at 84 weeks versus tirzepatide 15 mg's 25.5% in the REDEFINE 4 head-to-head Phase 3 trial published in early August 2026. The August 4 H1 2026 earnings release raised full-year 2026 sales guidance to down 3% from a prior down 8% midpoint at constant exchange rates. The broader investor narrative continues to focus on Novo's ability to defend GLP-1 franchise economics against Eli Lilly's Q2 2026 $23 billion revenue blowout (+48% year-over-year), Foundayo (orforglipron) $98 million first commercial quarter, and retatrutide's 28.7% Phase 3 TRIUMPH-4 weight loss result at 68 weeks. Analyst attention now shifts to Novo's Wegovy 7.2 mg higher-dose FDA review, the amycretin oral amylin monotherapy Phase 1b program (roughly 22% weight loss at Week 36), and next-generation candidates in Novo's pipeline. Investors are also watching the CagriSema FDA decision expected late 2026 and whether the label expansion strategy can offset the competitive pressure.

Industry · View digest

Q2 2026 Peptide-and-Obesity Earnings Week Wrap: Merck (MRK) $16.61B Revenue Beat + Raised Guidance With LIPFENDRA Launch Focus and $5.7B Terns Acquisition Charge; Pfizer (PFE) $15B Revenue Beat + Raised Guidance With Obesity Program Momentum; Amgen (AMGN) $10.05B Revenue Beat + Raised Guidance and Discontinued AMG 513 Early-Stage Obesity Candidate Leaving MariTide as Sole Focus; Eli Lilly (LLY) $23B Revenue (+48%) Blowout + Raised Guidance to $85-87B With Foundayo $98M First Commercial Quarter; Novo Nordisk (NVO) H1 78.49B DKK ($12.09B) + Raised Guidance but Shares -5% on Margin Concerns; Alnylam (ALNY) Extends 30% Selloff on Amvuttra Guidance Cut + Eplontersen Setback

The peptide-and-obesity Q2 2026 earnings week (Merck August 4, Pfizer August 4, Amgen August 4, Eli Lilly August 5, Novo Nordisk H1 August 4-5) delivered mixed signals across the pharma sector. Merck (NYSE: MRK) posted $16.61 billion Q2 revenue (+5% YoY, beat consensus by $250M), raised FY revenue guidance to $66.3-67.3 billion but cut adjusted EPS guidance to $2.66-2.76 due to a $5.7 billion Terns Pharmaceuticals acquisition charge; Keytruda reached $8.37 billion (+5%) and LIPFENDRA (enlicitide) launched at $315/month with $5 billion peak sales potential by 2034. Pfizer (NYSE: PFE) reported $15 billion revenue and $0.77 adjusted diluted EPS, raised FY revenue guidance midpoint to $60.5-62.5 billion, and CEO Bourla said the obesity program (danuglipron plus Metsera pipeline) is advancing with substantial momentum. Amgen (NASDAQ: AMGN) reported $10.05 billion Q2 revenue (+10% YoY), raised FY guidance to $38.2-39.4 billion, discontinued AMG 513 early-stage obesity candidate leaving MariTide as sole obesity focus. Eli Lilly (NYSE: LLY) delivered $23 billion Q2 revenue (+48% YoY blowout), raised FY guidance to $85-87 billion, Mounjaro reached $9.9 billion (+91%), Zepbound $4.9 billion US (+44%), and Foundayo generated $98 million in first fully operational commercial quarter. Novo Nordisk H1 reached 78.49 billion DKK ($12.09 billion, +3% CER) with Wegovy pill at 5 million+ prescriptions and raised guidance; NVO shares fell 5% on margin concerns. Alnylam (NASDAQ: ALNY) extended a 30% selloff (approximately $12 billion market cap lost) since the July 30 Q2 report on the Amvuttra TTR guidance cut plus eplontersen setback.

Industry · View digest

Eli Lilly (NYSE: LLY) Reports Q2 2026 Earnings Wednesday August 5 With Revenue of $23 Billion (+48% Year-Over-Year), Full-Year 2026 Revenue Guidance Raised to $85-87 Billion From Prior $82-85 Billion; Mounjaro (Tirzepatide) Type 2 Diabetes Revenue Rose 91% to $9.9 Billion ($4.8B US + $5.2B International), Zepbound (Tirzepatide) Obesity Revenue Reached $4.9 Billion US (+44% YoY on Strong Prescription Volume More Than Offsetting Price Declines), Foundayo (Orforglipron) Generated $98 Million in Its First Fully Operational Commercial Quarter Since the April 2026 FDA Approval; Combined Mounjaro + Zepbound Franchise Reached $14.9 Billion for the Quarter, and LLY Shares Rose Approximately 4% Intraday

Eli Lilly (NYSE: LLY) reported Q2 2026 earnings Wednesday August 5, 2026 with revenue of $23 billion (+48% year-over-year), well ahead of analyst consensus of $20.5 billion. Full-year 2026 revenue guidance was raised to $85-87 billion from the prior $82-85 billion range. Mounjaro (tirzepatide for type 2 diabetes) revenue rose 91% to $9.9 billion, split $4.8 billion US and $5.2 billion international, with the international majority driven by aggregate international Mounjaro market share now above 50% per prior Lilly executive commentary. Zepbound (tirzepatide for obesity) delivered $4.9 billion in US revenue (+44% year-over-year), with strong prescription-volume growth more than offsetting the low-to-mid-teens price erosion Lilly had guided to for FY26. Foundayo (orforglipron, the first oral small-molecule GLP-1 receptor agonist approved by FDA in April 2026) generated $98 million in its first fully operational commercial quarter, providing the first commercial-earnings-line view of the oral small-molecule GLP-1 category. Combined Mounjaro + Zepbound franchise revenue reached $14.9 billion, representing approximately 65% of total Lilly revenue for the quarter. LLY shares rose approximately 4% intraday on the earnings and guidance beat. Analyst commentary flagged the substantial widening of the Lilly-Novo obesity franchise gap.

Industry · View digest

Eli Lilly (NYSE: LLY) Q2 2026 Earnings Preview for Wednesday August 5 With Analyst Consensus at $20.5 Billion Revenue and $7.74 EPS Alongside Novo Nordisk H1 2026 Results the Same Day; Primary Analyst Focus Numbers Include Foundayo (Orforglipron) Weekly Prescription Volumes Near 20,000 as the Initial Commercial Ramp Indicator, Mounjaro Sales Trajectory (Q1 2026 Mounjaro + Zepbound Combined $12.82 Billion, ~65% of Lilly Total Revenue), Full-Year 2026 Revenue Guidance Currently at $83-85 Billion, and the Q1 2026 Novo Nordisk Wegovy Pill $354 Million Baseline

Eli Lilly (NYSE: LLY) reports Q2 2026 earnings Wednesday August 5, 2026 before market open with analyst consensus at $20.5 billion revenue and $7.74 EPS. Primary analyst focus numbers: Foundayo (orforglipron) weekly prescription volumes near 20,000 as the initial commercial ramp indicator following the April 2026 FDA approval as the first oral small-molecule non-peptide GLP-1 receptor agonist; Mounjaro (tirzepatide, type 2 diabetes indication) and Zepbound (tirzepatide, obesity indication) sales trajectory (Q1 2026 combined revenue $12.82 billion, approximately 65% of Lilly total revenue, driven by U.S. commercial volume plus international expansion with aggregate international Mounjaro market share now north of 50% per Lilly executive commentary at Goldman Sachs Healthcare Conference); full-year 2026 revenue guidance currently at $83-85 billion for potential revision; and the international pricing pressure headwind with management guiding low-to-mid-teens price erosion for FY26. Novo Nordisk reports H1 2026 results the same Wednesday August 5. Wegovy pill (oral semaglutide 25 mg for obesity) Q1 2026 sales of approximately $354 million provide the H1 baseline for the Novo pill franchise; injectable Wegovy Q1 2026 sales were $18.2 billion Danish kroner (+12% YoY).

Industry · View digest

Q2 2026 Earnings Preview for the Peptide-and-Obesity Big Three Next Week: Merck (NYSE: MRK) Reports Tuesday August 4 With Analyst Consensus at $1.36 Diluted EPS Down 36.2% YoY From $2.13 (Reflecting Post-Keytruda Loss-of-Exclusivity Repositioning and LIPFENDRA/Enlicitide Launch Costs), Eli Lilly (NYSE: LLY) Reports Wednesday August 5 With Analyst Consensus at $20.26 Billion Revenue and $6.71 EPS (Prediction Markets Show 70% Probability of Another Earnings Beat, 96.4% Odds Mounjaro Clears $7.5 Billion Q2, 87% Odds Zepbound Tops $4 Billion Q2, and Foundayo Weekly Prescriptions Near 20,000 as the Analyst Focus Number), and Novo Nordisk Reports Wednesday August 5 H1 2026 Results

Q2 2026 earnings from the peptide-and-obesity big three arrive next week. Merck (NYSE: MRK) reports Tuesday August 4 before market open with analyst consensus at $1.36 diluted EPS (down 36.2% year-over-year from $2.13 in Q2 2025), reflecting post-Keytruda loss-of-exclusivity strategic repositioning and LIPFENDRA (enlicitide, oral macrocyclic peptide PCSK9 inhibitor approved July 16, 2026) launch costs. Eli Lilly (NYSE: LLY) reports Wednesday August 5 before market open with analyst consensus at $20.26 billion revenue and $6.71 EPS. Prediction markets put a 70% probability on another Lilly earnings beat, 96.4% odds Mounjaro (tirzepatide) clears $7.5 billion Q2, 87% odds Zepbound (tirzepatide) tops $4 billion Q2, and Foundayo (orforglipron, oral small-molecule GLP-1) weekly prescriptions near 20,000 as the primary analyst focus number after the April 2026 FDA approval. Novo Nordisk reports Wednesday August 5 H1 2026 results (Novo reports half-year rather than quarterly), with Wegovy pill (oral semaglutide 25 mg) Q1 2026 sales of approximately $354 million providing the H1 baseline. The three earnings prints together will frame second-half 2026 obesity market trajectory and the competitive positioning across incretin, macrocyclic peptide, and small-molecule oral GLP-1 franchises.

Industry · View digest

Medicare GLP-1 Bridge Program Marks 27 Days Since the July 1, 2026 CMS Pilot Launch That Provides All Formulations of Wegovy (Semaglutide, Novo Nordisk), the KwikPen Formulation of Zepbound (Tirzepatide, Eli Lilly), and All Formulations of Foundayo (Orforglipron, Eli Lilly) at a Capped $50 Monthly Copay for Eligible Medicare Part D Beneficiaries Through December 31, 2027; KFF Analysis Estimates Approximately 3.8 Million Medicare Beneficiaries Meet the Clinical Eligibility Criteria for the Program (~8% of the 47.5 Million Part D Enrollees Nationally), Though CMS Has Not Yet Released Actual Enrollment Data From the First Program Month

The Centers for Medicare & Medicaid Services (CMS) Medicare GLP-1 Bridge Program is 27 days into the July 1, 2026 pilot launch. The program provides eligible Medicare Part D beneficiaries access to specified GLP-1 receptor agonist products at a capped $50 monthly out-of-pocket cost through December 31, 2027. Covered products include all formulations of Wegovy (semaglutide, Novo Nordisk), the KwikPen formulation of Zepbound (tirzepatide, Eli Lilly), and all formulations of Foundayo (orforglipron, Eli Lilly). The program was created through a Most-Favored-Nation (MFN) pricing agreement announced by the Trump administration in Q1 2026 that pairs manufacturer discounts with a fixed patient copay. A KFF (Kaiser Family Foundation) analysis estimates approximately 3.8 million Medicare beneficiaries meet the program's clinical eligibility criteria (obesity with BMI ≥ 30 kg/m² and specific cardiovascular or metabolic comorbidities), representing approximately 8% of the 47.5 million Part D enrollees nationally. CMS has not yet released actual enrollment data from the first program month. The program's actual utilization pattern, adherence rate, and expenditure trajectory will inform whether the pilot is extended past December 31, 2027 or converted to a permanent Medicare Part D obesity benefit.